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Linezolid resistance mediated by the cfr gene in MRSA represents a global concern.
We investigated relevant phenotype differences between cfr-positive and -negative
MRSA that contribute to pathogenesis, and the efficacy of linezolid-based combination
therapies in murine models of bacteremia and skin and skin structure infection
(SSSI). As a group, cfr-positive MRSA exhibited significantly reduced susceptibilities
to the host defense peptides tPMPs, human neutrophil peptide-1 (hNP-1), and
cathelicidin LL-37 (P < 0.01). In addition, increased binding to fibronectin (FN) and
endothelial cells paralleled robust biofilm formation in cfr-positive vs. -negative MRSA.
In vitro phenotypes of cfr-positive MRSA translated into poor outcomes of linezolid
monotherapy in vivo in murine bacteremia and SSSI models. Importantly, rifampicin
showed synergistic activity as a combinatorial partner with linezolid, and the EC50 of
linezolid decreased 6-fold in the presence of rifampicin. Furthermore, this combination
therapy displayed efficacy against cfr-positive MRSA at clinically relevant doses.
Altogether, these data suggest that the use of linezolid in combination with rifampicin
poses a viable therapeutic alternative for bacteremia and SSSI caused by cfr-positive
multidrug resistant MRSA.
Keywords: MRSA, cfr, phenotype, biofilm, bacteremia, skin and skin structure infection, combination therapy
INTRODUCTION
MRSA is particularly challenging due to its inherent pathogenicity and multidrug resistant
phenotypes contributing to a variety of infectious diseases, ranging from skin and skin structure
infection (SSSI) to bacteremia (Tong et al., 2015; Wang et al., 2019). An increased global incidence
of MRSA infections associated with high mortality has been observed over the past decades (Bassetti
et al., 2014; Hassoun et al., 2017). For example, in the United States, S. aureus is most often
contracted as a nosocomial infection leading to more than 80,000 illnesses and 11,000 deaths yearly
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(Lepak and Andes, 2016). Therefore, new alternative strategies for
the treatment of such infections are urgently needed.
Linezolid has become an important drug for treating
nosocomial infections due to MRSA, including those with
reduced vancomycin susceptibility (e.g., VISA) (Dryden,
2011). However, linezolid resistance due to acquisition of
the cfr (chloramphenicol and florfenicol resistance) gene has
compromised MRSA treatment options (Long et al., 2006). The
cfr gene encodes a 23S rRNA methyltransferase that confers
combined resistance to phenicols, lincosamides, oxazolidinones,
pleuromutilins, and streptogramin A (PhLOPSA phenotype)
(Long et al., 2006; Witte and Cuny, 2011). In addition, there
is only a low fitness cost to the host for cfr carriage and this
facilitates its spread (LaMarre et al., 2011). Infections due to
cfr-positive MRSA are increasing and pose a serious threat to the
clinical success of oxazolidinone antibiotics (Witte and Cuny,
2011). Although the level of resistance to linezolid conferred
by cfr is moderate, the ability of cfr to enhance bacterial
survival in the presence of linezolid has been shown in vivo
in a murine pneumonia model (Zhou et al., 2018). Linezolid-
resistant MRSA strains carrying cfr were also associated
with prolonged use of linezolid in patients (Endimiani et al.,
2011). These data suggest that in addition to the cfr-mediated
linezolid resistance, cfr-positive MRSA may possess phenotypes
associated with pathogenesis that contribute to poor in vivo
treatment outcomes.
In this study, we profiled relevant phenotype differences
between cfr-positive and -negative MRSA that contribute to
bacteremia and SSSI. We examined whether these MRSA
were susceptible to host defense cationic peptides (HDP)
and assayed their biofilm forming abilities and binding
to fibronectin (FN) and endothelial cells. In addition, we
correlated in vitro phenotypes to linezolid resistance in vivo in
murine SSSI and bacteremia models to characterize cfr-positive
and -negative MRSA.
MATERIALS AND METHODS
Bacterial Strains and Background
Information
Ten well-characterized MRSA strains were used in this study (Li
et al., 2018; Zhou et al., 2018). Human clinical MRSA strains
(161402, 161400, 161494, and 161813) were kindly provided
by the Third Affiliated Hospital of Sun Yat-sen University
(Guangzhou, China) that obtained from hospitalized patients
with pulmonary infections. MRSA strains of animal origin (N50,
6Y2C, HYP6, N4-2, HYXC4, and 2B3) were collected from blood
and abscess cultures of sick animals at the Animal Diagnostic
Laboratory of South China Agricultural University. All strains
were identified by MALDI-TOF MS system (Ostergaard et al.,
2015). Four MRSA strains of human origin were typed as ST
764 and spa-type t1081, and the remaining six strains were
typed as ST 398 and ST 9 (Li et al., 2018; Zhou et al.,
2018). The ST 764 MRSA has emerged as a novel hybrid
variant of the ST 5 HA-MRSA lineage with the characteristics
of CA-MRSA in Asia, causing invasive infections (necrotizing
fasciitis and bacteremia) in both hospital and community settings
(Takano et al., 2013). The ST 398 MRSA has been reported in
China and Europe that was responsible for zoonotic infections
in patients with pneumonia and SSSIs (Stegger et al., 2010;
van der Mee-Marquet et al., 2011).
Linezolid-Based Combination
Susceptibility Testing and Time-Kill
Curves
The MICs of linezolid and other ten antibiotics (oxacillin,
cefotaxime, amikacin, azithromycin, tetracycline, vancomycin,
clindamycin, retapamulin, ciprofloxacin, and rifampicin)
against clinical MRSA isolates were conducted by the broth
microdilution method as recommended (CLSI, 2015). S. aureus
ATCC 29213 served as the quality control strain. Fold reduction
in MIC was determined by dividing the MIC of the antibiotic
alone by its MIC in the presence of 0.5 mg/L linezolid. Three
biological replicates were done for each combination and
the means of fold reduction were used for generating heat
maps. In vitro interactions between linezolid and rifampicin
were evaluated by the checkerboard method, and a fractional
inhibitory concentration index (FICI) of ≤0.5 was deemed
synergistic (Zhou et al., 2018).
In vitro time-kill curves were performed to compare the
activity of linezolid and rifampicin alone and in combination
against two representative cfr-positive and -negative strain sets.
In brief, a starting inoculum of ∼106 cfu/mL logarithmic phase
MRSA cells was used to expose to linezolid (16 mg/L) with or
without rifampicin (0.5 mg/L). The drug concentrations were
chosen to mimic the free serum steady-state peak concentrations
(fCmax) at the usual clinical doses in human (i.e., 600 mg for
linezolid, 300 mg for rifampicin) (Andes et al., 2002; Sirgel
et al., 2005; Chik et al., 2010; Dryden, 2011). MRSA densities
were determined by the serial viable counts collected over 24 h
incubation and expressed as log10 cfu/mL. Synergistic effect was




Concentration-effect curves were used to evaluate linezolid
potency against cfr-positive and -negative MRSA. Briefly, an
overnight culture of MRSA cell was washed, adjusted to 0.5
McFarland units and diluted in cation-adjusted Mueller Hinton
broth to a final density of 106 cfu/mL. The testing procedure
consisted of two groups, and each group included tubes with
two-fold increasing concentrations of linezolid from 0.015 to
32 mg/L, in the presence and absence of 0.5 × MIC rifampicin.
After 16 h of incubation at 37◦C, absorbance of each tube
was measured at OD600nm to quantify bacterial growth and
normalized with the no drug control. The relationship between
linezolid concentrations and antibacterial potency was calculated
using the Hill sigmoid Emax equation: E = Emax + (E0 –
Emax)/1 + 10∧[(log EC50 – C) × Hill slope] using GraphPad
Prism 8 software (Zhou et al., 2017).
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In vitro HDP Susceptibility
The tPMPs were prepared from thrombin-stimulated platelets
isolated from fresh rabbit blood and their bioactivity was
quantified using Bacillus subtilis ATCC 6633 as previously
described (Yeaman et al., 1992). Human neutrophil peptide-
1 (hNP-1) and cathelicidin LL-37 were purchased from
Peptides International (Louisville, KY, United States) and
Eurogentec (Fremont, CA, United States), respectively. In vitro
HDP susceptibilities were assessed by adding tPMP (2 mg/L
equivalent) to 103 cfu/mL MRSA cells and hNP-1 (5 mg/L) or LL-
37 (20 mg/L) to 105 cfu/mL MRSA cells (Xiong et al., 2009; Seidl
et al., 2011a). The HDP concentrations were selected to cover the
peptide concentrations that did not rapidly kill MRSA cells over
2 h of incubation based on previous studies (Seidl et al., 2011a).
Results were expressed as the percentage of the initial inoculum
that survived exposure to HDPs.
Adherence to Fibronectin and
Endothelial Cells
Six-well tissue culture plates were coated using 50 mg/L purified
human FN (Sigma Chemical, St. Louis, MO, United States)
overnight at 4◦C, and then treated with 3% bovine serum
albumin for 3 h to prevent non-specific adhesion (Xiong et al.,
2009). The human microvascular endothelial cell line (HMEC-
1) was cultured as previously described (Seidl et al., 2012).
Logarithmic-phase MRSA cells were added to FN-coated plates
(5 × 103 cfu/mL) and endothelial cell monolayer-coated plates
(5× 105 cfu/mL; MOI = 1:1), and then incubated for 1 h at 37◦C
under static conditions. For FN binding assay, unbound bacteria
were removed by washing the plates with PBS, and melted tryptic
soy agar (TSA; 2 mL) was added into each well and allowed
to solidify. For endothelial cell binding assay, unbound bacteria
were removed by washing the plates with Hanks balanced salt
solution (HBSS) and permeabilized using 1.0% Triton X-100
(Seidl et al., 2012), after which bacterial numbers per well were
determined by serial dilutions and plating on TSA. Adherence
was expressed as the percentage of the initial inoculum bound.
Biofilm Formation, Extracellular
Polysaccharide (EPS) and DNA
Determinations
The ability of MRSA to form biofilm was determined as described
previously (Seidl et al., 2011a). Briefly, overnight cultured MRSA
at 0.5 McFarland units (∼108 cfu/mL) was diluted 1:100 into
brain heart infusion (BHI) broth supplemented with 0.5%
glucose. 200 µL of the suspension was transferred into 96-
well plates and incubated for 18 h at 37◦C. After incubation,
the plates were washed with PBS, air dried and stained with
0.1% safranin. The adhering dye was dissolved in 30% acetic
acid, and absorption was measured at OD490nm to quantify
biofilm formation.
The water-soluble and -insoluble EPS synthesized by the
biofilms was examined using the anthrone-sulfuric method
(Chen et al., 2016). Briefly, 24 h biofilms were rinsed, removed
and dispersed by sonication at 20 kHz for 5 s. The suspension was
centrifuged at 6000 × g for 10 min at 4◦C, and the supernatant
was collected for water-soluble EPS determinations. The pellets
were resuspended in PBS, washed and air-dried to ensure all
the water-soluble EPS was discarded. The dry weight of each
biofilm was measured to adjust biomass differences between
cfr-positive and -negative MRSA. The water-insoluble EPS was
extracted using 1.0 M NaOH under agitation for 2 h at 37◦C
and quantified using an anthrone-sulfuric acid colorimetric assay
(Chen et al., 2016).
Release of extracellular DNA (eDNA) was determined from
18 h MRSA biofilm using a microplate fluorescence assay with
Hoechst dye 33258 (Leggate et al., 2006). Protocols for extraction
and purification of eDNA from MRSA biofilms were described
in detail elsewhere (Rice et al., 2007). The eDNA was quantified
using an EnSight fluorescence plate reader at Ex350/Em460
(PerkinElmer, Waltham, MA, United States). Purified salmon
sperm DNA was used to generate a standard curve. To
account for differences in biomass, the average OD490nm of each
unwashed biofilm was determined to calculate the amount of
eDNA per relative biomass.
Hemolytic Activity and Nuclease
Production
Hemolytic activity was evaluated by spotting 2 µL of MRSA
suspension (∼108 cfu/mL) onto 5% sheep blood agar plates
and incubated at 37◦C for 24 h (Seidl et al., 2011b). The
diameters of the zones of clearance (cm) indicating hemolytic
activity were measured. Nuclease production was assessed by
spotting 15 µL of filtered culture supernatants of the strains
into wells cut into DNase test agar (Beenken et al., 2010). Plates
were incubated overnight at 37◦C. Nuclease activity was then
assessed by overlaying the agar with 1 M HCl to precipitate
undigested DNA and define the zone diameters (cm) of clearance
(Beenken et al., 2010).
In vivo Murine Bacteremia and SSSI
Models
Six-week-old, pathogen-free female ICR mice (25–27 g from
Guangdong Medical Lab Animal Center, Guangzhou, China)
were used in this study. All animal experimental procedures were
approved by the South China Agricultural University (SCAU)
Institutional Ethics Committee (2017B075 and 2017018) and
performed in accordance with the SCAU Institutional Laboratory
Animal Care and Use guidelines. For bacteremia model, mice
were infected via the tail vein with a 0.5 mL bacterial suspension
delivering ∼105.5−6.0 cfu/mouse (Thakker et al., 1998). For SSSI
model, 0.1 mL of bacterial suspension consisting of ∼107.0 cfu
was inoculated subcutaneously into the flanks of mice (Tseng
et al., 2011). Four representative MRSA strains were selected for
in vivo studies based on their in vitro phenotypes and MLST types
that included cfr-positive and -negative MRSA.
To assess the therapeutic efficacy of linezolid and rifampicin
alone and in combination, mice were randomized at 24 h
(bacteremia model) and 48 h (SSSI model) post-infection to
receive: (i) no therapy (control); (ii) linezolid at 100 mg/kg, orally
twice daily; (iii) rifampicin at 5 mg/kg, orally twice daily; or (iv)
a combination of linezolid and rifampicin. The linezolid and
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rifampicin doses were selected to mimic the pharmacokinetic
profiles of recommended human clinical doses (i.e., 600 mg
and 300 mg, orally twice daily for linezolid and rifampicin,
respectively) (Chik et al., 2010; Zhou et al., 2018). Treatments
lasted for 3 and 5 days for the bacteremia and SSSI models,
respectively. Groups of five or six mice were included at each
dose regimen. Control and antibiotic-treated mice were sacrificed
either at the beginning of treatment (untreated controls) or 12 h
after the last antibiotic dose, respectively. At sacrifice, the target
tissues (blood, spleen and kidney for bacteremia model, and
skin abscess for SSSI model) were removed and quantitatively
cultured. Bacterial densities in infected tissues were calculated
as the mean log10 cfu/g. of tissue and log10 cfu/mL of blood
(± SD). In addition, the mean areas of superficial skin lesions
were quantitated for statistical comparisons in the SSSI model.
Statistical Analysis
In vitro studies were performed with three biological replicates
in triplicate. Two-tailed Student’s t-test was used to compare
relevant phenotype differences between cfr-positive and -negative
MRSA groups. Mann-Whitney non-parametric test was used to
analyze MRSA densities in target tissue among different groups.
RESULTS
Linezolid-Based Combination
Potentiated Activity Against cfr-Positive
MRSA
As expected, all the study MRSA isolates were resistant to
oxacillin with MICs ranging from 8 to 128 mg/L. The MICs
of linezolid were markedly higher in MRSA isolates harboring
the cfr gene (1–8 mg/L) than in those lacking the cfr (0.5–
2 mg/L; Table 1). Fold reductions in MICs of amikacin and
vancomycin were observed for part of cfr-positive MRSA isolates
when combined with the sub-MIC levels of linezolid at 0.5 mg/L.
However, the broad-spectrum antibiotics including cefotaxime
and ciprofloxacin displayed a limited MIC reduction. Notably,
in the presence of linezolid, rifampicin achieved the highest
therapeutic potential as a combinatorial partner with a greater
than 8-fold reduction in MIC against 8/10 MRSA isolates,
and this was independent of cfr expression (Figure 1A). The
combination of linezolid and rifampicin resulted in synergistic
activity against 5/6 cfr-positive MRSA isolates and 2/4 cfr-
negative MRSA isolates, with FICIs ranging from 0.375 to
0.5 (Table 1).
Control cultures increased ∼3-log10 cfu/mL for both cfr-
positive and -negative MRSA over a 24 h of incubation.
Rifampicin alone had the similar bacterial growths vs. their
control groups (Supplementary Figure S1). Of note, despite
having the same MICs, linezolid alone at 16 mg/L resulted in
greater bacterial killing for cfr-negative strain HYXC4 (1.70-
log10 cfu/mL) vs. the cfr-positive strain 6Y2C (0.78-log10 cfu/mL;
Supplementary Figure S1). Importantly, the combination of
linezolid (16 mg/L) and rifampicin (0.5 mg/L) showed a
synergistic bactericidal effect compared to each drug alone
regardless of the presence of cfr gene (Supplementary Figure S1).
For cfr-negative MRSA group, the 50% maximal killing effect
occurred at an average linezolid concentration of 0.71 mg/L
(Figure 1B) and this decreased 3.4-fold to 0.21 mg/L in the
presence of sub-MIC levels of rifampicin (Supplementary Table
S1; paired t-test, P < 0.01). Expression of the cfr gene increased
linezolid concentrations required to achieve 50% maximal effect
to 2.01 mg/L and were significantly higher than the cfr-negative
test group (Table 2; P < 0.05). However, when combined with
rifampicin, the concentration of linezolid required to achieve
50% maximal effect was only 0.34 mg/L for cfr-positive MRSA
group (Figure 1C). In fact, this level was comparable to the
concentration required to potentiate rifampicin for cfr-negative
TABLE 1 | Genotypic summary and MICs for study MRSA isolates.
MRSA strains MLST spa types MIC (mg/L)a FICIb
OXA LZD RIF
cfr-positive
161402 ST764 t1084 128 8 1 0.375
161494 ST764 t1084 128 4 1 0.5
N50 ST764 t899 32 2 8 0.25
6Y2C ST398 t7829 16 2 8 0.5
HYP6 ST9 t899 64 1 0.12 0.5
N4-2 ST9 t899 32 1 16 0.75
cfr-negative
161400 ST764 t1084 32 1 0.5 0.5
161813 ST764 t1084 32 0.5 1 0.75
HYXC4 ST398 t7880 8 2 4 0.375
2B3 ST9 t899 64 1 0.25 0.625
ATCC strain
29213 ST5 t002 0.25 1 0.008 0.5
aOXA, oxacillin; LZD, linezolid; RIF, rifampicin. b Interpreted as synergy (FICI ≤ 0.5), no interaction (0.5 < FICI ≤ 4) or antagonism (FICI > 4).
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FIGURE 1 | Linezolid-based combination susceptibility testing and potency analysis. (A) Heat map showing the mean fold reduction of MIC in the presence of
0.5 mg/L linezolid for MRSA strains. The strains carrying the cfr gene are underlined; Concentration-effect analysis of linezolid against cfr-negative (B) and cfr-positive
(C) MRSA strains in the presence (red) and absence (black) of 0.5 × MIC rifampicin. Data were shown as mean with 95% CIs from three biological replicates.
group (Table 2). Although the concentration of 0.34 mg/L
linezolid was insufficient to inhibit growth of MRSA carrying
the cfr gene, its combination with rifampicin provided a
promising alternative to overcome MRSA infections irrespective
of cfr expression.
In vitro HDPs Susceptibility and
Adherence to FN and Endothelial Cells
As a group, the cfr-positive MRSA exhibited significantly higher
survival rates after exposure to 2 mg/L tPMP (73.8%) or 5 mg/L
hNP-1 (78.5%) compared with the cfr-negative strain group
(43.1 and 57.7%, respectively; P < 0.01). Similarly, a markedly
reduced LL-37 killing was observed in cfr-positive vs. cfr-negative
MRSA group (P < 0.005; Figure 2A). The cfr-positive MRSA
demonstrated significantly higher binding rates to FN (14.8%)
compared with the cfr-negative MRSA (4.02%; P < 0.005),
despite a relatively low adherence to FN observed with the
cfr-positive strain N4-2. Consistent with FN binding profiles,
cfr-positive MRSA strain group bound substantially better to
human endothelial cells than cfr-negative group (11.30 vs. 3.87%,
P < 0.005; Figure 2B).
Biofilm Formation, EPS and eDNA
Determinations and Nuclease
Productions
We compared cfr-positive and -negative MRSA strain groups
with respect to in vitro biofilm capacity and composition. Overall,
the cfr-positive MRSA group had a greater ability to form biofilms
TABLE 2 | Calculated EC50 and Hill slope (N) values representing the antimicrobial potency of linezolid alone or with 0.5 × MIC rifampicin against cfr-positive and
-negative MRSA strains.a
Hill plot PD parameters
MRSA strains Linezolid alone Linezolid + 0.5 × MIC rifampicin
EC50b N R2 EC50c N R2
cfr+ 2.01 ± 0.53 3.95 ± 0.46 0.95 ± 0.02 0.34 ± 0.15 4.22 ± 0.54 0.96 ± 0.02
cfr− 0.71 ± 0.18 3.53 ± 0.87 0.94 ± 0.02 0.21 ± 0.05 3.66 ± 1.03 0.97 ± 0.02
aEC50, the linezolid concentration required to achieve 50% of maximal effect (Emax); N, the Hill coefficient that described the slope of the dose-response curve. bP < 0.05
for EC50 of linezolid alone in cfr-positive vs. -negative strains. cP < 0.01 for EC50 of linezolid and rifampicin in combination vs. linezolid alone.
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FIGURE 2 | Relevant phenotype differences between cfr-positive and -negative MRSA strain. (A) In vitro susceptibilities to tPMP, hNP-1, and LL-37; (B) Adherence
to immobilized FN and HMEC-1. (C) Biofilm formation by the study MRSA isolates based on absorbance values (OD490nm). (D,E) Water-soluble and insoluble EPS
and eDNA present in static biofilms. (F) Nuclease production and hemolytic activity of the study MRSA isolates on DNase agar and sheep blood agar plates,
respectively. Diameters of zones clearance (cm) are indicated. Each dot represents one strain with three biological replicates. All data are presented as means ± SD.
P, cfr-positive MRSA; N, cfr-negative MRSA (∗P < 0.01; ∗∗P < 0.005).
compared with the cfr-negative group (OD490nm 1.51 vs. 0.33,
P < 0.01; Figure 2C). The production of the water-soluble EPS
ranged from 161 to 593 µg/g, with the average production in cfr-
positive group being considerably higher than that in cfr-negative
group (487 µg/g vs. 202 µg/g, P < 0.01). A similar pattern was
observed for the water-insoluble EPS between cfr-positive and
-negative strain groups (P < 0.01; Figure 2D). Of note, the 24 h
old MRSA biofilms showed increased production of the water-
soluble EPS compared to water-insoluble EPS in both groups.
In addition, the average amount of eDNA present in the cfr-
positive MRSA biofilms (10.6± 1.37 ng) was 2.1-fold greater than
that present in the cfr-negative MRSA biofilms (4.96 ± 0.88 ng),
a statistically significant difference (P < 0.005; Figure 2E).
These results were further corroborated by a significantly lower
level of nuclease production in the cfr-positive MRSA group
(P < 0.005; Figure 2F). In addition, except for strain 161494,
the cfr-positive MRSA strain group possessed more α-hemolysin
activity, compared with weak or non-detectable α-hemolysin
production in cfr-negative MRSA group (Figure 2F).
In vivo Responsiveness to Linezolid and
Rifampicin Alone and in Combination
In the murine SSSI model, MRSA densities in skin abscesses and
the areas of skin lesions in mice infected with cfr-negative MRSA
isolates 161400 and HYXC4 were significantly reduced after
5 days of linezolid monotherapy as compared to their untreated
controls (P < 0.005, Figure 3). In contrast, for cfr-positive
MRSA isolates 161402 and 6Y2C, the mice did not respond
to linezolid monotherapy and residual abscess-tissue MRSA
densities and the areas of skin lesions similar to those in their
respective controls (Figure 3). Of note, combination therapy
with linezolid and rifampicin resulted in 1.5–3.6 log10 cfu/abscess
reductions in MRSA densities vs. linezolid monotherapy against
both cfr-positive and -negative MRSA infections (Figures 3A,C).
This result occurred despite the lower MRSA densities in skin
abscesses observed in cfr-negative isolates (P < 0.05; Figure 3).
In the bacteremia model, we found the similar results.
Linezolid monotherapy resulted in uniform and highly
significant reductions of MRSA densities in all the target
tissues of mice infected with cfr-negative MRSA isolates 161400
and HYXC4. For instance, a ≥2.0 log10 cfu/mL reductions in
blood density and ≥1.0 log10 cfu/g reductions in spleen and
kidney densities were observed with linezolid monotherapy
as compared to their respective control mice infected with
cfr-negative MRSA (P < 0.01). However, bacteremia caused by
cfr-positive MRSA isolates showed the opposite results: (i) a
≥1.0 log10 cfu/g increases in both spleen and kidney (161402,
Figures 4A,B) or (ii) no response to linezolid monotherapy,
with similar residual target-tissue MRSA densities compared
with untreated controls (6Y2C; Figures 4D–F). Importantly, the
combination of linezolid and rifampicin showed efficacies higher
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FIGURE 3 | Therapeutic efficacy of linezolid (LZD; 100 mg/kg twice daily) or rifampicin (RIF; 5 mg/kg twice daily) alone and in combination in a murine SSSI model
due to cfr-positive (161402 and 6Y2C) and -negative (161400 and HYXC4) MRSA strains. Each dot represents MRSA density in each skin abscess (A,C) or the area
of each skin lesion (B,D), and the horizontal lines represent the means of observations from groups of five mice (two abscesses per mouse).
than each monotherapy in mice infected with both cfr-positive
and -negative MRSA (P < 0.001; Figure 4).
DISCUSSION
S. aureus is a common opportunistic pathogen that causes
a wide range of infections affecting skin and soft tissues as
well as invasive infections that include bacteremia, endocarditis
and pneumonia (Bassetti et al., 2014; Hassoun et al., 2017).
In particular, bacteremia caused by MRSA is often associated
with a high mortality rate, even with appropriate antibiotic
treatments (Seidl et al., 2011a). Linezolid has been an important
drug for therapy of MRSA infection. However, the emergence
and rapid spread of horizontally transferable cfr determinant
in MRSA has become a substantial concern (Witte and
Cuny, 2011). The effective therapeutic alternatives were limited,
especially for the vancomycin-intermediate and linezolid-
resistant MRSA carrying cfr gene (Barber et al., 2016).
Fortunately, unlike the chromosomally encoded resistance
mechanisms, cfr has been shown to confer the low-level resistance
to linezolid (Locke et al., 2014). Therefore, the combination
therapy is an appealing option for retaining the clinical
utility of linezolid.
Linezolid is a valuable alternative to glycopeptide antibiotics
(e.g., vancomycin) and an oral formulation allows a rapid
intravenous to oral switch (Dryden, 2011; Bassetti et al., 2014).
As described in previous clinical studies, linezolid achieved
significantly greater efficacy (e.g., higher cure rates) and earlier
discharges from hospital than vancomycin treatment in patients
with MRSA-complicated SSSI (Sharpe et al., 2005). This clinical
outcome may be ascribed to a good penetration into skin
and soft tissues with almost 100% oral bioavailability (Bassetti
et al., 2014). Furthermore, linezolid treatments for MRSA
bacteremia had roughly equivalent clinical and microbiological
outcomes compared with vancomycin (Shorr et al., 2005). In our
previous pneumonia model, addition of rifampicin to linezolid
significantly decreased fAUC/MIC targets in both plasma and
lung epithelial lining fluid (Zhou et al., 2018). Here, we extended
the effectiveness of linezolid and rifampicin combination to
the clinically relevant murine models of SSSI and bacteremia
due to cfr-positive and -negative MRSA. More importantly,
rifampicin decreases S. aureus FN binding that is a further
advantage of the combination therapy (Rasigade et al., 2011).
Frontiers in Microbiology | www.frontiersin.org 7 January 2020 | Volume 10 | Article 3080
fmicb-10-03080 December 31, 2019 Time: 13:30 # 8
Zhou et al. Combination Therapy for cfr-Positive MRSA
FIGURE 4 | MRSA densities in spleen (A,D), kidney (B,E), and blood (C,F) in the murine bacteremia model due to cfr-positive (161402 and 6Y2C) and -negative
(161400 and HYXC4) MRSA strains with linezolid or rifampicin mono- and combination therapies (LZD at 100 mg/kg, RIF at 5 mg/kg, orally twice a day for 3 days,
starting at 24 h post-infection). Each dot represents one mouse, and the horizontal lines indicate the means of observations from groups of six mice.
This is supported by other studies showing successful clinical
outcomes with oral linezolid and rifampicin combination therapy
in the management of recurrent and persistent MRSA bacteremia
(Schwalm et al., 2004).
Indeed, we observed significant phenotype differences
between cfr-positive and -negative MRSA that contribute to
bacteremia and SSSI. The capability of S. aureus to circumvent
clearance mediated by locally secreted HDPs is an important
factor for its pathogenicity (Seidl et al., 2011a). In the current
study, we demonstrated that cfr-positive MRSA isolates tended to
be more resistant to key innate HDPs from neutrophils (hNP-1),
platelets (tPMPs), and epithelial cells (LL-37), compared with
the cfr-negative MRSA isolates. These findings suggested that
cfr-positive MRSA might be more capable to survive in the
bloodstream early in the course of skin infections. In particular,
survival rates of >40% after 2 h of exposure to HDPs were
positively correlated with the severity of endovascular infections
and reduced responsiveness to antimicrobial therapy (Yeaman
et al., 1992; Seidl et al., 2011a). Similarly, we observed a dramatic
relationship between the reduced HDP killing in vitro and
decreased efficacy of linezolid-based therapy in the murine
bacteremia model.
Interestingly, cfr-positive MRSA group exhibited greater
biofilm formation and higher EPS and eDNA productions
compared with cfr-negative strain group. Biofilms enhance
bacterial resistance to HDPs and antibiotics due to poor
penetration past this barrier and this was the case for cfr-positive
MRSA (Donlan and Costerton, 2002). Cathelicidin LL-37 can
protect against MRSA-induced skin infections but cfr-positive
MRSA were also able to resist the adverse effects of LL-37
exposure (Haisma et al., 2014). The alterations may contribute
to the poor outcomes of linezolid therapy in mice infected with
cfr-positive MRSA isolates in the SSSI model.
Invasive S. aureus must attach to extracellular matrix ligands
or surface proteins on host cells to enable adhesion and
internalization (Xiong et al., 2009). Therefore, the ability to
bind FN is necessary for inducing S. aureus infections (e.g.,
bacteremia) (Seidl et al., 2011a). Consistent with this, increased
FN binding of cfr-positive MRSA correlated with worse outcomes
of linezolid-based mono- and combination therapies in the
murine bacteremia model. This observation is also in line with
previous reports that the development of a hyper-adhesive FN
binding phenotype contributed to persistent MRSA bacteremia
and infective endocarditis (Xiong et al., 2009, 2015). In addition,
we found that cfr-positive MRSA isolates adhered better than
cfr-negative isolates to human endothelial cells, and this may
facilitate MRSA colonization and provide an advantage in the
pathogenesis of invasive MRSA infections.
The exact mechanisms how the presence of cfr correlates with
the phenotypic characteristics remain to be fully elucidated. In
the recent past, it was assumed that the development of antibiotic
resistance was linked to virulence and fitness costs (Beceiro et al.,
2013). However, the acquisition of cfr in S. aureus has been
associated with low fitness cost that potentially facilitates the
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growth rates, invasiveness and transmission capacity (LaMarre
et al., 2011; Beceiro et al., 2013). In addition, in most of
our study MRSA strains, cfr co-expressed with the erm gene
(erythromycin resistance) that has a significant correlation
with biofilm formations (Beceiro et al., 2013; Li et al.,
2018). Previous studies in Enterococcus species exhibited that
strong biofilm formation was more prevalent among linezolid-
resistant compared with -sensitive isolates (Osman et al.,
2020). S. aureus is a highly adaptable bacterium capable of
dynamic changes in its virulence and resistance phenotypes
when exposure to the host defenses or antibiotics (Abdelhady
et al., 2015). Thus, additional unknown mechanisms likely
contribute to the adaptive response phenotypes in vitro
and linezolid-associated outcomes in vivo. Studies including
comparative genomic and transcriptomic analysis are in
progress in our laboratories to further determine other
possible mechanisms.
Our investigation has several limitations. For example, we
assessed a relatively small number of cfr-positive and -negative
MRSA strains despite the different clonal types that raise
the possibility of strain-dependent bias. In addition, some
strains were isolated from animals and we only examined
four representative MRSA strain sets in our animal models.
Future studies should examine the phenotypic characteristics
and usefulness of this combination in a larger population of
strains from patients and in the clinical settings. Moreover,
based on current findings, we do not know whether the
relationship between the phenotypic profiles and the outcome
of linezolid-based treatment is “cfr specific” or other unknown
mechanisms. Although this is beyond the scope of the
present study, future mechanism-based studies is warranted
to better understand the precise factors responsible for this
potential correlation.
Of note, the previous study reported that bacteriostatic-
bactericidal antibiotic combinations could result in attenuation
of bactericidal activity (Lobritz et al., 2015). However, our
results showed the synergistic bactericidal effect for linezolid
and rifampicin combination. This is supported by the previous
observation that the combination of linezolid and rifampicin
resulted in 3.1-log10 cfu/mL killing in vitro against staphylococcal
biofilm (El Haj et al., 2018). Similarly, linezolid used in
combination with rifampicin was more effective than their
monotherapies, reducing the planktonic MRSA cells by >3.0
log10 cfu/mL in the cage fluids of foreign-body infections
(Baldoni et al., 2009). In light of the divergent effects that
observed between our results and previous study, future
investigation is warranted to better understand the precise
mechanism of this combination.
In summary, our results indicated that increased FN and
endothelial cell adhesion, reduced susceptibility to HDPs and
robust biofilm formation all contributed to linezolid treatment
outcomes we found in vivo. Combination therapy with linezolid
and rifampicin significantly enhanced therapeutic efficacy against
experimental bacteremia and SSSI due to cfr-positive and
-negative MRSA isolates.
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